Candel Therapeutics Opens Another $50 Million Share-Sale Program After Using Its Previous Capacity
Jefferies will earn a 3% sales commission, while Candel controls when to request sales and the minimum prices.
Candel Therapeutics, which develops experimental virus-based cancer treatments, renewed its program Thursday to sell up to $50 million in additional shares. Its SEC filing put sales under the predecessor program at approximately $50 million—the earlier program's limit.
Another Round Through Jefferies
The renewed capacity comes on top of proceeds Candel already received. Jefferies, the company's sales agent, will handle common-stock sales over time through an at-the-market offering—a way to issue shares into the trading market.
Candel began the financing arrangement with Jefferies on August 5, 2022, and revised the agreement on August 14, 2025. Thursday's renewal continues that existing financing relationship.
Jefferies will earn 3% of gross sale proceeds. The agent agreed to make reasonable efforts to place shares, but has no commitment to sell a particular quantity or dollar amount. Actual financing therefore depends on sales being requested and completed.
Candel Controls The Sale Instructions
Candel can request sales in installments and set minimum prices. Either Candel or Jefferies can pause sales, although transactions already executed must still settle.
The agreement permits negotiated sales with Candel's consent, as well as sales on existing trading markets. Candel cannot submit sale instructions while it holds material information that has not been made public.
For existing shareholders, completed sales would add shares to the outstanding total and reduce the ownership percentage represented by each existing share. Candel receives the sale proceeds after the commission is deducted.
Viruses In The Cancer Pipeline
Candel's treatments use engineered viruses delivered into tumors to prompt an immune response against cancer. Its clinical platforms rely on modified adenovirus and herpes simplex virus.
Its most advanced candidate, aglatimagene, is under study for prostate cancer and non-small cell lung cancer. Linoserpaturev is being tested against recurrent high-grade glioma, a brain cancer.
Candel also uses its enLIGHTEN discovery platform to develop additional experimental treatments. It owns development and commercialization rights across its programs in major markets, including the United States, Europe and Asia.
Candel must report the number of shares sold and net proceeds in quarterly or annual reports, or in prospectus supplements filed at least quarterly.